The Kinderformularium, developed in the Netherlands, now also provides pediatricians and pharmacists abroad with a database of drug dosage recommendations specifically aimed at treating children. Germany, Austria and Norway are the first countries in which the Kinderformularium has been rolled out. All parties signed a license agreement with the Dutch Children's Formulary NKFK (Nederlands Kenniscentrum Farmacotherapie bij Kinderen).
Saskia de Wildt, Medical Director and Pediatrician, Professor of Clinical Pharmacology at the Radboudumc: 'The Children's Formulary is unique. It has taken a lot of time and effort to set it up properly and carefully and to develop it further. For this we worked together with a large network of Dutch physicians and pharmacists. We received financial support from various parties, and since 2017 the Ministry of Health, Welfare and Sport has been funding our Dutch activities.'
'It requires continuous monitoring to see if the data is still up to date and meets all the conditions of medication for children. I am very proud and happy that the Children's Formulary is now also used outside the Netherlands and that this allows us to share our child-specific drug dosage information system with other countries. We look forward to other countries joining us so that we can also contribute to safer and more effective drug care for children there.
Customization possible per country
It is possible to adapt the system to the needs of the country concerned. All countries carefully checked the existing content, and where necessary, the database was expanded to include medicines that are not used in the Netherlands but are used in the country in question.
Tjitske van der Zanden, technical director of the Children's Formulary and researcher at Radboudumc and Erasmus MC: "The ultimate goal is to collaborate on content. By drawing up the dosage recommendations together we can divide the work, speed up the maintenance cycle and further expand the information, for example with dosages for obese children or children born prematurely. For us, the most important thing is that we can ensure that children in all countries receive the right medication in the right dosage, this is a great first step!'
Related news items
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more
Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path16 September 2021
The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.read more
Infections increase risk to develop dementia16 September 2021
In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.read more